Coutinho MF et al. Glycosaminoglycan storage diseases: a review. Biochem Res Int 2012; 471325.
Meikle PJ et al. Prevalence of lysosomal storage disorders. JAMA 1999; 281(3): 249–254.
Morishita K, Petty RE. Musculoskeletal manifestations of mucopolysaccharidoses. Rheumatol 2011; 50 suppl 5: v19–v25.
Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 2011; 50(5): v4–v12.
National Institute of Neurological Disorders and Stroke. Mucopolysaccharidoses Fact Sheet, 2015. Available at: www.ninds.
nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Mucopolysaccharidoses-Fact-Sheet [accessed: April 2017].
White KK. Mucopolysaccharidoses: etiology, classification, deformities unique to each type, treatment modalities and
indications for surgical intervention. Spine Deform 2012: Sept; 114–118.
Wraith JE. Chapter 39: Mucopolysaccharidoses and oligosaccharidoses. In: Fernandes J, Saudubray JM, van den Berghe G,
Walter JH (eds). Inborn Metabolic Diseases. Diagnosis and Treatment. 4th edn. Springer-Verlag, Heidelberg, 2006.
Wraith JE et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in
the era of enzyme replacement therapy. Eur J Pediatr 2008; 167(3): 267–277.
The information on this website is related to a Takeda initiative which aims to support MPS Awareness Day 2019 and raise awareness of MPS and related diseases. This information should not be used in place of advice from your family doctor or other healthcare professional. If in doubt, please contact your doctor for advice. MPSDay.com has been produced by Takeda and is for US audiences only. The website has been developed in accordance with industry and legal standards to provide information on the above-mentioned initiative. Takeda makes every reasonable effort to include accurate and current information. However, the information provided on the website is not exhaustive.